Company information
Name, CVR number, address, industry and legal form are based on the Danish Central Business Register (CVR).
CVR / VirkThe information about FORWARD PHARMA A/S combines official Danish company and financial-statement data with indicators calculated by Valuatum Oy.
Name, CVR number, address, industry and legal form are based on the Danish Central Business Register (CVR).
CVR / VirkFinancial figures come from annual reports published through the Danish Business Authority. The latest financial year used is 2024.
Open the 2024 annual reportValuatum Oy calculates financial ratios, comparisons and credit-risk indicators from the available accounts. The results support analysis and do not constitute a standalone credit decision.
Valuatum OyFORWARD PHARMA A/S (CVR number: 2886588-0) is a company from KØBENHAVN. The company recorded a gross profit of -9457.9 kDKK in 2024. The operating profit was -11.3 mDKK, while net earnings were 75.9 mDKK. The profitability of the company measured by Return on Assets (ROA) was -0.8 %, which can be considered poor but Return on Equity (ROE) was 16.6 %, which can be considered excellent. The equity ratio, a key indicator for solidity, stood at 58.5 %, a level that can be considered to be modest. This means a balanced mix of debt and equity financing its assets—a typical operational level for many companies. FORWARD PHARMA A/S's liquidity measured by quick ratio was 1.6 which is at a very high level. Thus, the company demonstrates exceptional financial stability, possessing a significant surplus of liquid assets over its short-term liabilities.
2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Volume | |||||
| Net sales | |||||
| Gross profit | -7 763.73 | -10 812.93 | -11 631.79 | -6 130.61 | -9 457.91 |
| EBIT | -24 320.79 | -24 879.26 | -14 706.28 | -7 957.63 | -11 296.04 |
| Net earnings | -42 201.69 | -12 271.14 | -31 482.85 | -3 832.52 | 75 927.65 |
| Shareholders equity total | 474 106.68 | 461 863.38 | 430 396.73 | 426 445.78 | 488 330.23 |
| Balance sheet total (assets) | 574 865.81 | 561 060.28 | 529 878.49 | 704 684.59 | 835 352.48 |
| Net debt | - 160 864.47 | - 155 145.83 | - 145 880.41 | - 141 174.82 | -74 601.92 |
| Profitability | |||||
| EBIT-% | |||||
| ROA | -4.0 % | -2.0 % | -5.6 % | 1.0 % | -0.8 % |
| ROE | -8.5 % | -2.6 % | -7.1 % | -0.9 % | 16.6 % |
| ROI | -4.0 % | -2.0 % | -5.6 % | 1.0 % | -0.8 % |
| Economic value added (EVA) | -54 988.76 | -53 493.66 | -42 753.22 | -34 471.63 | -43 396.75 |
| Solvency | |||||
| Equity ratio | 82.5 % | 82.3 % | 81.2 % | 60.5 % | 58.5 % |
| Gearing | 20.1 % | 20.8 % | 22.6 % | 65.1 % | 70.5 % |
| Relative net indebtedness % | |||||
| Liquidity | |||||
| Quick ratio | 2.6 | 2.6 | 2.5 | 1.5 | 1.6 |
| Current ratio | 2.6 | 2.6 | 2.5 | 1.5 | 1.6 |
| Cash and cash equivalents | 256 198.49 | 251 430.66 | 243 125.59 | 418 740.26 | 418 983.25 |
| Capital use efficiency | |||||
| Trade debtors turnover (days) | |||||
| Net working capital % |
Check the creditworthiness of FORWARD PHARMA A/S before offering payment terms. The report combines financial figures, risk scores, credit rating, bankruptcy risk and a credit-limit recommendation in one PDF.
Automatic monthly billing is under development. The feature is not yet active in our system, but it is coming soon. You get access to the service immediately after registration, while billing is handled manually by email invoice for now.
By pressing the button below, you confirm that you have read the terms above and allow us to invoice you 20 EUR / month.
The AI Credit Risk Report contains the same core financial figures and risk measures as the Credit Risk Report. It also provides written analysis of the company's finances, risks, repayment capacity and assets, together with relevant context from web searches.
Company-specific, AI-assisted credit risk report in PDF format.
Reports can be tailored to your own credit process: content structure, peer groups, risk thresholds, delivery method and AI-analysis weightings can all be adapted to your needs.
Ask about a tailored solution: contact@creditreports.dk
The report is intended for an initial financial assessment. · The final credit decision and any further verification are always the user's responsibility. · One-time payment, no subscription.
Pay by card and the report is generated automatically and sent to your email. One-time payment – no subscription.
The report is sent to the email address you enter in Stripe's payment window. Please also check your spam folder. Questions? Write to info@creditreports.dk.